Neuralstem (CUR)
Neuralstem Market Cap: 51.40M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CUR Market Cap Rankings
| Overall | 14th percentile | 3957 of 4649 |
| Sector | 19th percentile | 422 of 525 in Healthcare |
| Industry | 19th percentile | 132 of 163 in Biotechnology |
CUR Market Cap Range, Past 5 Years
| Minimum | 31.51M | Mar 2009 |
| Maximum | 115.95M | Sep 2010 |
| Average | 69.72M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these CUR related companies
CUR News
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
May 09, 9:15AM PR Newswire
May 09, 9:15AM PR Newswire
Neuralstem Chief Scientific Officer To Present At Spinal Cord Injury Conference In China
Apr 25, 9:15AM PR Newswire
Apr 25, 9:15AM PR Newswire
NEURALSTEM ANNOUNCES 2011 FINANCIAL RESULTS, PROVIDES OPERATIONS UPDATE
Mar 29, 4:26PM Thomson Reuters ONE
Mar 29, 4:26PM Thomson Reuters ONE
Neuralstem ALS Stem Cell Trial Interim Results Reported in the Journal, STEM CELLS
Mar 28, 9:15AM PR Newswire
Mar 28, 9:15AM PR Newswire
URGENT: $CUR filed to delay releasing annual earnings results (SEC Filing Form NT 10K) http://stks.co/2t1N
about 74 days ago by MarketBrief
about 74 days ago by MarketBrief
Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
Feb 08, 9:05AM PR Newswire
Feb 08, 9:05AM PR Newswire
$CUR http://stks.co/1bOk Positive divergence should launch CUR nicely for sustainable upside for the weeks and months ahead.
about 161 days ago by KeySpeculator
about 161 days ago by KeySpeculator
$CUR http://stks.co/1OiL Positive divergence on weekly and daily charts says bounce; shareholder conference on tap this week.
about 175 days ago by KeySpeculator
about 175 days ago by KeySpeculator
Neuralstem says first patient dosed in cervical region in ALS stem cell trial
Nov 23, 9:17AM FlyOnTheWall
Nov 23, 9:17AM FlyOnTheWall
Neuralstem Reports Third Quarter Financial Results and Provides Business and Clinical Update
Nov 09, 4:05PM PR Newswire
Nov 09, 4:05PM PR Newswire
Neuralstem completes Phase Ia in NSI-189 major depressive disorder trial
Oct 27, 9:17AM FlyOnTheWall
Oct 27, 9:17AM FlyOnTheWall
Neuralstem (CUR) Shares Jump 6% Following FDA Approval to Dose in Cervical Region
Oct 24, 9:18AM Street Insider
Oct 24, 9:18AM Street Insider
Neuralstem gets FDA approval to dose patients in cervical region in ongoing
Oct 24, 9:18AM FlyOnTheWall
Oct 24, 9:18AM FlyOnTheWall
Neuralstem (CUR) Gets FDA Approval to Advance Spinal Stem Cell Phase I
Oct 24, 9:16AM Street Insider
Oct 24, 9:16AM Street Insider
Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
Oct 24, 9:15AM PR Newswire
Oct 24, 9:15AM PR Newswire
$CUR filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/ktZ
about 218 days ago by MarketBrief
about 218 days ago by MarketBrief
CEPH beat and raised. Massive short interest. Trillion dollar #stemcells drug approved. See Yahoo MB. $GERN $CUR $ALSE $BMTI $KCI $KNSY
about 471 days ago by stemcellcure
about 471 days ago by stemcellcure
Neuralstem $CUR shares on the move as co. receives FDA orphan drug designation for its spinal cord stem cells for the treatment of ALS
about 474 days ago by Street_Insider
about 474 days ago by Street_Insider
@stockwhisperers $ASTM very cheap marketcap wise vs. $ACTC $STEM $GERN $CUR and ASTM has Phase3 pending-upside would be here in the 100%s
about 529 days ago by biotech
about 529 days ago by biotech
$CUR news out on IDN for phase 1 safety clinical trial for chronic spinal cord injury treatment using spinal cord stem cells..
about 642 days ago by tokyoseminole
about 642 days ago by tokyoseminole
$CUR http://beta.chart.ly/7f7j8pi breakout/pullback play.. watch that 2.6 level for a second breakout
about 662 days ago by mb_willoughby
about 662 days ago by mb_willoughby
$CUR http://beta.chart.ly/m2tehug breakout/pullback play.. watch that 2.6 level for a second breakout
about 662 days ago by mb_willoughby
about 662 days ago by mb_willoughby
Tweeting live tomorrow (Tue) from our stem cell investor & executive event in NY http://bit.ly/dvUF63 $ATHX $ASTM $PSTI $STEM $CUR #biotech
about 728 days ago by MDBpartners
about 728 days ago by MDBpartners
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CUR | 0.94 | -0.01 | -1.05% | 51.40M |
| CUK | 32.44 | +0.02 | +0.06% | 6.977B |
| CUBE | 11.44 | +0.00 | +0.00% | 1.405B |
| CUBA | 6.84 | +0.01 | +0.15% | |
| CUB | 43.69 | -0.36 | -0.82% | 1.168B |
| CU | 25.03 | -0.13 | -0.52% | |
| DEI | 21.89 | -0.17 | -0.77% | 3.056B |
| DEG | 39.37 | +0.51 | +1.31% | 4.011B |
| DEF | 27.68 | +0.06 | +0.21% | |
| DEER | 2.97 | +0.08 | +2.77% | 99.76M |
